ArticleOncogene2013
The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- An induced pluripotent stem cell model of Schwann cell differentiation reveals NF2- related gene regulatory networks.Research square · 2025Article
- Large, recursive membrane platforms are associated to Trop-1, Trop-2, and protein kinase signaling for cell growth.Molecular biology of the cell · 2025Article
- Conformational flexibility determines the Nf2/merlin tumor suppressor functions.Matrix biology plus · 2021Article
- Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.Science signaling · 2019Article
- Identification of two distinct peptide-binding pockets in the SH3 domain of human mixed-lineage kinase 3.The Journal of biological chemistry · 2018Article
- Gene expression, signal transduction pathways and functional networks associated with growth of sporadic vestibular schwannomas.Journal of neuro-oncology · 2017Article
- Regulation of multidrug resistance by microRNAs in anti-cancer therapy.Acta pharmaceutica Sinica. B · 2017Review
- Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2016Review
- An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.Journal of neuro-oncology · 2016Article
- Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.Neuro-oncology · 2016Review
- Molecular insights into NF2/Merlin tumor suppressor function.FEBS letters · 2014Review
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.American journal of medical genetics. Part A · 2014Article
- Tumor suppressor NF2/Merlin is a microtubule stabilizer.Cancer research · 2014Article
- Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.Brain : a journal of neurology · 2013Article
- Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.Current opinion in otolaryngology & head and neck surgery · 2012Review
- Onco-Golgi: Is Fragmentation a Gate to Cancer Progression?Biochemistry & molecular biology journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Neurofibromatosis type 2 patients develop schwannomas, meningiomas and ependymomas resulting from mutations in the tumor suppressor gene, NF2, encoding a membrane-cytoskeleton adapter protein called merlin. Merlin regulates contact inhibition of growth and controls the availability of growth factor receptors at the cell surface. We tested if microtubule-based vesicular trafficking might be a mechanism by which merlin acts. We found that schwannoma cells, containing merlin mutations and constitutive activation of the Rho/Rac family of GTPases, had decreased intracellular vesicular trafficking relative to normal human Schwann cells. In Nf2-/- mouse Schwann (SC4) cells, re-expression of merlin as well as inhibition of Rac or its effector kinases, MLK and p38(SAPK), each increased the velocity of Rab6 positive exocytic vesicles. Conversely, an activated Rac mutant decreased Rab6 vesicle velocity. Vesicle motility assays in isolated squid axoplasm further demonstrated that both mutant merlin and active Rac specifically reduce anterograde microtubule-based transport of vesicles dependent upon the activity of p38(SAPK) kinase. Taken together, our data suggest loss of merlin results in the Rac-dependent decrease of anterograde trafficking of exocytic vesicles, representing a possible mechanism controlling the concentration of growth factor receptors at the cell surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.